Table 3.
Demographic and clinical characteristics of LTRs with stratification by antibody and neutralization responses after vaccination scheme completion. Seropositive LTRs with neutralization capacities assessed by sVNT were evaluated at day 238 (n = 9) as well as non-responders (n = 19). Seroneutralization against wild-type SARS-CoV-2 and the Delta and Omicron variants was recorded for LTRs with positive titers for least at one collection time point.
| LTRs, (n) | ||||||
|---|---|---|---|---|---|---|
| Seropositive with Neutralization Capacities (sVNT), (9) (%) | Seronegative, (19) (%) |
p-Value | With WT Neutralization Capacities, (24) (%) |
With Delta Neutralization Capacities, (13) (%) |
With Omicron Neutralization Capacities, (9) (%) |
|
| Age, years | ||||||
| 18–39 | 0 (0.0) | 1 (5.3) | ns | 1 (4.2) | 0 (0.0) | 1 (11.1) |
| 40–59 | 2 (22.2) | 2 (10.5) | 3 (12.5) | 1 (7.7) | 1 (11.1) | |
| ≥60 | 7 (77.8) | 16 (84.2) | 20 (83.3) | 12 (92.3) | 7 (77.8) | |
| Sex | ||||||
| Female | 6 (66.7) | 6 (31.6) | ns | 11 (45.8) | 5 (38.5) | 4 (44.4) |
| Male | 3 (33.3) | 13 (68.4) | 13 (54.2) | 8 (61.5) | 5 (55.6) | |
| Time since transplant, years | ||||||
| <1 | 0 (0.0) | 4 (21.0) | ns | 3 (12.5) | 1 (7.7) | 1 (11.1) |
| >1 | 9 (100) | 15 (79.0) | 21 (87.5) | 12 (92.3) | 8 (88.9) | |
| Initial respiratory disease | ||||||
| COPD | 8 (88.9) | 13 (68.4) | ns | 20 (83.4) | 11 (84.6) | 6 (66.7) |
| Pulmonary fibrosis | 0 (0.0) | 3 (15.8) | 2 (8.3) | 1 (7.7) | 1 (11.1) | |
| Other | 1 (11.1) | 3 (15.8) | 2 (8.3) | 1 (7.7) | 2 (22.2) | |
| Corticosteroids | ||||||
| 2–6 mg/day | 9 (100) | 15 (79.0) | ns | 23 (95.8) | 13 (100) | 9 (100) |
| ≥8 mg/day | 0 (0.0) | 4 (21.0) | 1 (4.2) | 0 (0.0) | 0 (0.0) | |
COPD, chronic obstructive pulmonary disease. ns, non-significant.